A quantitative index settles whether two tumours are clonally related

Design

Validation of an NGS-based clonal-relatedness index against phenotype-based assessment

Population

120 paired gastrointestinal, hepatopancreaticobiliary and peritoneal tumours from 60 patients

Primary outcome

Discriminating clonal from independent tumour pairs

Effect

Area under the curve 0.986; index sensitivity 96.2%, specificity 100% vs phenotype 71.2%/62.5%

Deciding whether a second carcinoma is a new primary or a metastasis changes staging and treatment, and morphology with immunohistochemistry is often inconclusive. This study validated a clonal-relatedness index built from next-generation sequencing data.

Using 120 paired gastrointestinal, hepatopancreaticobiliary and peritoneal tumours from 60 patients, the index was calculated as the share of shared alterations. Median values were 0.85 for clonal and 0.24 for non-clonal pairs, and the index separated the two with an area under the curve of 0.986. Against the gold standard, it reached 96.2% sensitivity and 100% specificity, far better than phenotype-based assessment (71.2% and 62.5%). The gap widened in hypermutable tumours, where phenotype collapsed (43% sensitivity) but the index held (86%).

For practice this gives pathologists a reliable, quantitative answer where morphology cannot decide, provided paired sequencing is available. It is an adjunct for the hard cases, especially hypermutable tumours, rather than a replacement for routine morphological assessment.

• A next-generation-sequencing clonal-relatedness index was validated on 120 paired GI, hepatopancreaticobiliary and peritoneal tumours.
• It separated clonal from independent tumours with an area under the curve of 0.986.
• Sensitivity was 96.2% and specificity 100%, versus 71.2% and 62.5% for phenotype-based assessment.
• In hypermutable tumours, phenotype sensitivity fell to 43% while the index held at 86%.
• Use it for hard cases where morphology cannot decide and paired sequencing is available.

Why it matters

Calling a second primary versus a metastasis changes stage and treatment, and this replaces a frequently inconclusive judgement with a quantitative one.

Don't overread it

Validated in 60 patients and dependent on paired next-generation sequencing, it is an adjunct for difficult cases, not a universal replacement for morphological assessment.

The statistics, in plain English

An area under the curve of 0.99 means near-perfect separation of clonal from independent tumours; the comparison shows the index outperforms phenotype most where phenotype is weakest, but these are 60 patients and the test needs paired sequencing.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.